US Pharma MarketingInhibrx opens door to cancer vaccine combo for its OX40 agonist
Inhibrx says INBRX-106 plus Keytruda beats Keytruda alone in HNSCC data, with cancer-vaccine combination trials planned for early 2027. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo…
Inhibrx Biosciences says its latest mid-stage results show the potential of its OX40 agonist in immunogenic cancers — but also its prospects in combination with cancer vaccines in tumors with lower immunogenicity.
“The next step for ...
Source: Endpoints News